MCL Literature Feed

This case links progressive necrotizing xanthogranuloma, a rare paraneoplastic syndrome, as the presenting sign of MCL, underscoring the need for hematologic workup for specific skin/ocular findings.

This preclinical study identifies SOX11 as an endogenous inhibitor of SAMHD1, which sensitizes mantle cell lymphoma to cytarabine, suggesting SOX11 status as a predictive biomarker for chemotherapy efficacy.

This case report describes mantle cell lymphoma presenting as multiple colonic polyposis causing obstruction, highlighting a rare gastrointestinal manifestation requiring specific immunohistochemical diagnosis for confirmation.

This B-ALL study reveals MALT1 inhibitors downregulate MYC, providing a novel mechanism and strong rationale for testing this strategy in aggressive, MYC-driven mantle cell lymphoma.

This case report describes indolent mantle cell lymphoma presenting with significant renal disease, highlighting a rare extranodal manifestation as the primary cause of organ dysfunction.

This phase 1/2 trial establishes the safety and efficacy of the BTKi acalabrutinib in Chinese patients with relapsed/refractory MCL, supporting its use in this specific population.

This commentary discusses the zandelisib (PI3Ki) plus zanubrutinib (BTKi) combination, suggesting a potential role for newer, potentially less toxic PI3K inhibitors in relapsed/refractory MCL.

Outpatient autologous stem cell transplantation is a feasible consolidation strategy for advanced MCL in a low-income, Latin American setting, providing important real-world evidence for resource-constrained systems.

This study defines the unique treatment patterns, clinical outcomes, and genomic landscape of Hepatitis B-associated MCL, providing crucial data for managing this complex patient subgroup.

An editor's note highlights a preclinical study where a combined epigenetic therapy shows superior efficacy against MCL cells, suggesting a novel therapeutic strategy for clinical development.

This review positions allogeneic transplant as a key curative option for high-risk (e.g., TP53-mutated) and relapsed/refractory MCL, despite its changing role with the advent of novel therapies.

In a European compassionate use program, pirtobrutinib demonstrated a 67% overall response rate and good safety in heavily pretreated, BTKi-exposed relapsed/refractory MCL, supporting its real-world clinical utility.

A rare, non-nodal MCL case with hairy cell-like features and a TP53 mutation showed an indolent course, challenging prognostic assumptions and emphasizing comprehensive genomic and pathologic evaluation.

This case report details severe glofitamab-induced ICANS with seizures in a heavily pre-treated MCL patient, highlighting CNS risk factors and successful management with anakinra and antiseizure drugs.

Brexucabtagene autoleucel (CAR-T) combined with BTK inhibitors is a potentially safe and effective strategy for treating relapsed mantle cell lymphoma with central nervous system involvement.

Real-world registry data from Ukraine (2019-2021) reports a 3-year overall survival of 61% for newly diagnosed MCL patients, providing a crucial benchmark for outcomes in this region.

Combining CAR-T therapy with a BTK inhibitor may offer a synergistic strategy to effectively treat mantle cell lymphoma with central nervous system involvement, a historically poor-prognosis population.

An indirect comparison suggests brexucabtagene autoleucel provides superior response rates and progression-free survival over pirtobrutinib for MCL patients who have failed a prior covalent BTKi.

The PI3Ki zandelisib plus BTKi zanubrutinib combination shows high efficacy (74% ORR, 47% CR) with manageable toxicity in relapsed/refractory MCL, offering a promising chemotherapy-free regimen.

This review provides a framework for integrating bispecific antibodies into MCL treatment, addressing the critical clinical question of how to sequence them with other novel immunotherapies like CAR-T.

The EHA/EBMT ICAHT grading system better predicts severe infections and mortality post-CAR-T than CTCAE, which is highly relevant as MCL patients showed the highest rates of severe hematotoxicity.

MNDA is highly expressed in nearly 80% of mantle cell lymphoma cases, but its utility in distinguishing MCL from marginal zone lymphoma is limited due to overlapping expression.

This preclinical study identifies DNMT3A-mediated metabolic reprogramming to oxidative phosphorylation as a novel ibrutinib resistance mechanism, which can be overcome by low-dose decitabine.

This meta-analysis across B-NHLs confirms lenalidomide-based regimens improve OS and PFS, supporting its established role in relapsed/refractory and maintenance settings for MCL.

This preclinical study identifies that SOX11 upregulates the antioxidant PRDX2, promoting chemoresistance in aggressive MCL, and suggests PRDX2 as a novel therapeutic target to overcome drug resistance.

This case report describes a rare presentation of primary, localized orbital mantle cell lymphoma successfully managed with local excision and radiotherapy, highlighting an unusual clinical scenario for this systemic disease.

A transplant-sparing frontline regimen of lenalidomide-R-CHOP/R-HiDAC showed favorable outcomes in TP53 wild-type high-risk MCL, but not TP53-mutated MCL, reinforcing the prognostic power of sequential MRD monitoring.

MYC overexpression is a critical biomarker defining high-risk mantle cell lymphoma, helping to stratify patients with poor prognosis and potentially guiding novel therapeutic approaches for this aggressive disease.

The CAR-T therapy lisocabtagene maraleucel demonstrates high, durable complete responses and a favorable safety profile in heavily pretreated, relapsed/refractory MCL, including high-risk patients.

This retrospective analysis shows peripheral blood Ig-HTS MRD testing (clonoSEQ) effectively predicts relapse earlier than imaging in MCL patients, supporting its use as a surveillance tool post-frontline therapy.